Sarepta Therapeutics Ord Shs (SRPT)
$169.96 0.19 (0.11%)
16:00 EDT SRPT Stock Quote Delayed 30 Minutes
Previous Close $170.15
Market Cap 11.14B
PE Ratio -57.81
Volume (Avg. Vol.) 450,474
Day's Range 166.88 - 171.23
52-Week Range 72.05 - 172.70
Dividend & Yield N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics Ord Shs News
- From InvestorPlace
- From the Web
Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its treatment for Duchenne muscular dystrophy.
These are stocks with extremely high potential returns. We are talking about upside potential of over 100%. And that’s not just according to my wild calculations. That’s according to the analysts covering these stocks.
Apple's health initiative can't keep key people and Sarepta Therapeutics' CLR are a couple more top news items about the stock market today.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Healthcare stocks recovered throughout 2018 but the recent correction in some big names is creating an entry point.
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Navellier RatingsPowered by Portfolio Grader